Merck KGAA says it will work to make Erbitux (cetuximab) available for patients in China as a first-line treatment for metastatic colorectal cancer (mCRC) as soon as possible. But it seems that the real benefit for the German company of any label expansion will be in helping build its brand presence in China rather than in absolute sales.
Erbitux was first approved in China for use in combination with irinotecan or as a single agent for mCRC refractory to irinotecan in 2006, but the standard first- and second-line...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?